| Literature DB >> 34203182 |
Mengxun Zhang1,2, Jiaqing Zhong1, Yongai Xiong3, Xun Song1, Chenyang Li1, Zhendan He1,4.
Abstract
Developing broad-spectrum antiviral drugs remains an important issue as viral infections continue to threaten public health. Host-directed therapy is a method that focuses on potential targets in host cells or the body, instead of viral proteins. Its antiviral effects are achieved by disturbing the life cycles of pathogens or modulating immunity. In this review, we focus on the development of broad-spectrum antiviral drugs that enhance the immune response. Some natural products present antiviral effects mediated by enhancing immunity, and their structures and mechanisms are summarized here. Natural products with immunomodulatory effects are also discussed, although their antiviral effects remain unknown. Given the power of immunity and the feasibility of host-directed therapy, we argue that both of these categories of natural products provide clues that may be beneficial for the discovery of broad-spectrum antiviral drugs.Entities:
Keywords: antiviral; immunomodulatory; natural products
Mesh:
Substances:
Year: 2021 PMID: 34203182 PMCID: PMC8310077 DOI: 10.3390/v13071257
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Structures of some broad-spectrum antiviral agents.
Figure 2Immune response during viral infections.
Antiviral effects of natural immunomodulatory products.
| Chemical Type | Compound Name | Antiviral Against | Mechanisms | Reference |
|---|---|---|---|---|
| Saponins | Astragaloside IV | CVB3 | Upregulated IFN-γ, inhibited NF-κB | [ |
| Saikosaponin A | Influenza virus, PCV2 | Downregulated NF-κB and promoted neutrophil and monocyte recruitment; upregulated IL-2 and IFN-γ and increased IgG and WBCs in serum | [ | |
| Saikosaponin D | PCV2 | Upregulated IL-2 and IFN-γ and increased IgG and WBCs in serum; activated macrophages | [ | |
| Ginsenoside Rb1 | EV71 | Increased TNF-α, IL-10, IFNs, and antibodies in serum | [ | |
| Terpenoids | Celastrol | SARS-CoV, HIV, DENV | Activated the JAK/STAT pathway and increased IFN-α | [ |
| Phenylpropanoids | Acteoside | VSV, influenza virus | Activated T-bet and increased IFN-γ; activated ERK to promote proliferation of lymphocytes | [ |
| Salidroside | CVB3, DENV, RSV | Increased IL-10 and IFN-γ, decreased TNF-α and IL-2; increased the expression of RIG-I and upregulated IRFs | [ | |
| Arctigenin | H1N1, PCV2, JEV, HIV, HSV | Activated the TLR6/NOX2/MAPK signaling pathway and activated macrophages | [ | |
| Arctiin | Influenza A | Increased antibody levels in serum | [ | |
| 4-Methoxy-cinnamaldehyde | RSV | Increased the secretion of IFN | [ | |
| Anthraquinones | Aloin | Influenza | Activated STAT, T-bet, and IFN-γ; increased the number of antigen-specific T cells | [ |
| Aloe-emodin | JEV, EV71 | Increased IFN-α | [ | |
| Flavonoids | Baicalin | H1N1 | Promoted the secretion of IFN-γ in T cells and NK cells | [ |
| Quercetin | HSV, influenza A, NDV, VSV | Increased type I IFN and IL-6 | [ | |
| Vitexin | Influenza virus | Upregulated TLR4 and increased IFN-β | [ | |
| Alkaloids | Matrine | PRRSV, PCV2 | Enhanced phagocytosis and lymphocyte proliferation | [ |
| Oxymatrine | HBV | Upregulated the TLR9 pathway, promoted maturation of dendritic cells, and increased IFN-γ, TNF-α, and IL-2 | [ | |
| Trolline | Influenza virus | Upregulated TLR4 and increased IFN-β | [ | |
| Polysaccharides | GP | BVDB | Promoted the expression of IRFs | [ |
| RIP | HSV-2, influenza A, HBV | Activated the JAK/STAT pathway and upregulated IFN-α | [ | |
| APS | Influenza A | Enhanced IL-1β, IL-10, IL-6, and TNF-α levels | [ |
Figure 3Structures of astragaloside IV, saikosaponins A and D, and ginsenoside Rb1.
Figure 4Structure of celastrol.
Figure 5Structures of acteoside, salidroside, arctigenin, arctiin, and 4-methoxycinnamaldehyde.
Figure 6Structures of aloin and aloe-emodin.
Figure 7Structures of baicalin, quercetin, and vitexin.
Figure 8Structures of matrine, oxymatrine, and trolline.
Small molecules that enhance immunity.
| Chemical Type | Compound Names | Immunomodulatory Effects | Reference |
|---|---|---|---|
| Saponins | Astragaloside II | Increased IFN-γ and IL-2 and promoted the proliferation and activation of T cells | [ |
| Astragaloside VII, | Increased IL-2 and IFN-γ and promoted the proliferation of splenocytes | [ | |
| Saikosaponins B1 and B2 | Activated macrophages | [ | |
| (−)-β-Sitosterol-3- | Promoted the secretion of IFN-γ in NK cells | [ | |
| Lablabosides A, B, and C | Adjuvant activity | [ | |
| Chikusetsusaponin IVa | Adjuvant activity | [ | |
| Terpenoids | Glycyrrhetinic acid | Promoted the expression of TLRs and upregulated downstream MyD88, IL-6, and IFN-β; enhanced the proliferation of lymphocytes | [ |
| Pentalinonsterol | Activated macrophages and DCs, increased proinflammatory cytokines, and increased antibodies | [ | |
| Andrographolide | Enhanced the formation of specific cytotoxic T lymphocytes | [ | |
| 14-Deoxy-11,12-didehydroandrographolide | Enhanced the innate immunity of intestinal epithelial cells | [ | |
| Cassiabudanols A and B | Promoted the proliferation of splenocytes and increased the ratio of CD4+ and CD8+ T cells | [ | |
| Cinnamomols A and B | Promoted the proliferation of T cells | [ | |
| Lycopene | Increased the proportion of CD4+ and CD8+ T cells and increased IL-2, TNF-α, and IFN-γ | [ | |
| Astaxanthin | Promoted the proliferation of lymphocytes, enhanced the activity of NK cells, and increased the production of antibodies | [ | |
| Phenylpropanoids | Chlorogenic acid | Activated macrophages via the calcineurin/NF-ATc/IL-2 pathway | [ |
| Phyllanthusmin C | Increased IFN-γ via the TLR/NF-κB pathway | [ | |
| Flavonoids | Icariin | Increased the production of antibodies, promoted the expression of TLR9 in macrophages, and downregulated inflammatory cytokines | [ |
| Rutin | Increased the population of CD4+ lymphocytes and promoted the secretion of IFN-γ | [ | |
| Chromanone | Gonytolide A | Activated innate immune system and increased the production of IL-8 | [ |
| the Alkaloids | 2-Formyl-5-(hydroxymethyl)-1H-pyrrole-1-butanoic acid; | Activated macrophages and increased TNF-α, IL-12, and NO | [ |
| Organosulfur compounds | Alliin | Promoted the proliferation of mononuclear cells and increased IL-1β | [ |
| Allicin | Increased proinflammatory cytokines and increased the populations of macrophages, DCs and CD4+ T cells | [ | |
| Diallyl disulfide | Increased WBCs and antibodies and led to more effector B cells | [ |
Figure 9Structures of astragalosides II and VII; macrophyllosaponin B; saikosaponins B1 and B2; (−)-β-sitosterol-3-O-β-D-(6-O-palmitoyl)glucopyranoside; lablabosides A, B, and C; and chikusetsusaponin IVa.
Figure 10Structures of glycyrrhetinic acid, pentalinonsterol, andrographolide, 14-deoxy-11,12-didehydroandrographolide, cassiabudanols A and B, cinnamomols A and B, lycopene, and astaxanthin.
Figure 11Structures of chlorogenic acid and phyllanthusmin C.
Figure 12Structures of icariin and rutin.
Figure 13Structures of gonytolide A and its derivatives.
Figure 14Structures of pyrrole alkaloids.
Figure 15Structures of organosulfur compounds.
Chemical details of polysaccharides.
| Plant | Polysaccharide | Molecular Weight | Constituents | Reference |
|---|---|---|---|---|
|
| Verbascose | 0.83 kDa | Glu, Gal | [ |
| Acemannan | 1.66 kDa | Man, Gal | [ | |
|
| MAP | 8 kDa | Man, Gal, Glu | [ |
| Aloeride | 4000–7000 kDa | Glu (37.2%), Gal (23.9%), Man (19.5%), Ara (10.3%) | [ | |
|
| F1 | 103 kDa | Man, Glu, Gal, Ara | [ |
| F2 | 628 kDa | [ | ||
| PSP | - | Major: Gal, Rha | [ | |
| - | 1334 kDa | Rha, Ara, Glc, Gal, Gal (0.03:1.00:0.27:0.36:0.30) | [ | |
| - | 5.6 kDa | Glc, Gal, Ara, Xyl, Gal (10.0: 1.3: 1.7: 1.0: 0.9) | [ | |
| SCPP11 | 3.4 kDa | Man, Glu, Gal (1:11.38:3.55) | [ | |
| Crude | - | Glu (38.0%), Gal (36.7%), galacturonic acid (12.0%), Ara (7.3%), Rha (4.0%), Man (1.2%), glucuronic acid (0.6%). | [ | |
| CVT-E002 | - | Poly-furanosyl-pyranosyl-saccharides | [ | |
| GL-4IIb2 | 11 kDa | 15 different monosaccharides | [ | |
| Crude | - | Major: Ara:Gal:Glu:Rha = 6.35:3.15:1.47:1 | [ | |
| D3-S1 | 2000 kDa | Major: Ara:Gal = 2.6:1.0 | [ | |
|
| PV2IV | - | Ara, Xyl, Man, Gal, Glu | [ |
| P1 | - | Ara (28.37%), Xyl (54.67%), Man (5.61%), Glu (5.46%), Gal (5.89) | [ | |
| AS-1 | - | Man, Gal, Ara, Glu | [ | |
| AAP70-1 | 2.72 kDa | Glu, Fru | [ | |
|
| PMA | - | - | [ |
| Crude | - | Glu:Man:Ara:Gal:Xyl:Rha:ribose = 250:66:6:3.25:2.5:1.25:1 | [ | |
|
| Fucoidan | <10 kDa | Sugar (72.16% ± 0.31%), uronic acid (1.42% ± 0.03%), amino acids (7.04% ± 0.47%), sulfate (16.62% ± 1.31%) | [ |
|
| PS-G | - | Major: Glu, Man | [ |
| POP1 | 8.1 kDa | Rha (5.74%), Ara (12.58%), Man (10.97%), Glu (64.96%), Gal (6.55%) | [ | |
|
| ACP | 70 kDa | - | [ |
|
| SHIP-1 | - | Man:Glu:Gal:Ara:l-fucose = 1.92:1.00:2.37:0.44:1.13 | [ |
| SHIP-2 | - | Glu:Gal:l-fucose = 1.0:0.61:0.83 | [ | |
|
| BP-1 | 67 kDa | - | [ |
|
| CCP | 1970 kDa | Man (48.73%), Gal (17.37%), Glu (15.97%), Xyl (17.93%) | [ |
|
| PPS | - | Man, Glu, Gal | [ |
|
| C30–60% | - | Glu (96.76%), Man (2.91%), Ara (0.24%), Ribose (0.04%), Gal (0.04%), Xyl (0.01%) | [ |
|
| JNY2PW | 52500 kDa | - | [ |
|
| HEP | - | Man (2.5%), glucuronic acid (1.1%), Glu (60.9%), Gal (28.0%), Fru (7.5%) | [ |
|
| GFP | 155 kDa | Rha:Xyl:Man:Glu = 1.00:1.04:1.11:6.21 | [ |
| Longan ( | LP | 377 kDa | Gal (40.88%), Ara (38.26%), Glu (9.00%), Rha (5.49%), Xyl (1.60%), ribose (1.05%), Fuc (0.91%) | [ |
| Sesbania cannabina | Galactomannan | 216 kDa | Gal:Man = 1.6:1 | [ |
| Medicago sativa L. | APS | - | Fuc, Ara, Gal, Glu, Xyl, Man, galacturonic acid, glucuronic acid | [ |
| BP100 III.1 | 24 kDa | Ara:Rha:Fuc:Xyl:Man:Gal:GalA = 7.9:22.6:1.1:5.0:2.0:20.0:38.5 | [ | |
| BP1002 | 64 kDa | Rha (9.8%), Gal (10.5%), Ara (15.6%), Xyl (10.8%), galacturonic acid (45.8%) | [ | |
| BPII | - | Major: GalA (65.1%) | [ |
Abbreviations: Man, mannose; Glu, glucose; Gal, galactose; Ara, arabinose; Rha, rhamnose; Xyl, xylose; Fuc, fucose; Fru, fructose.